The Company is a designated supplier, providing cGMP psilocybin to Project Solace participants
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce its participation in Project Solace, launching in Canada this July. A collaboration between Canadian non-profit TheraPsil and the UK’s Drug Science, the project will be the largest medical psilocybin and data project to date, providing a safe supply of psilocybin to patients in medical need.
Project Solace aims to expand legal access to psilocybin medicine for Canadian patients suffering from conditions such as end-of-life distress, Major Depressive Disorder and other serious conditions for which traditional treatment options have failed. While doing this, Project Solace aims to develop a substantial body of evidence, using a real-world data (RWD) registry, to document clinical effectiveness, safety, and clinician and patient reported outcomes in patients who have received psilocybin-assisted psychotherapy by access to psilocybin through Canada’s Special Access Program (SAP).
Project Solace will begin assisting patients in five primary regions in British Columbia, Ontario and Quebec, with plans to expand as additional treatment teams are on boarded. Patients will be connected to prescribing healthcare professionals who can request cGMP psilocybin from designated suppliers enrolled in Project Solace, including HAVN Life, Filament Health and Psygen.
Health Canada has designated the Special Access Program (SAP), along with clinical trials, as a preferred pathway for patients to access psilocybin for medical purposes. Under SAP, prescribing healthcare professionals can request psilocybin, manufactured by Health Canada-approved licensed dealers, for seriously-ill patients who require emergency access to this medicine.
“We are honored to participate in Project Solace, the first-of-its-kind that will provide thousands of Canadians with a life-changing opportunity to receive psilocybin assisted therapy,” says HAVN Life CEO Tim Moore. “Projects like these speak to the very foundation of HAVN Life, which is to support and serve communities in need of cognitive and mental health treatment alternatives and help them achieve their full potential. We are excited to be part of this potentially transformative effort on the path towards full Health Canada approval,” he adds.
The anonymised data collected through Project Solace will be provided to regulatory bodies including Health Canada, to facilitate decision-making surrounding the regulatory system for the future of medicalized psilocybin.
Data collected from Project Solace will be a critical tool for prescribing healthcare professionals, and help future patients decide which licensed producers of psilocybin products best suit their medical needs. The data will also be released to designated suppliers enrolled in the RWD program and the general public.
Havn Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin containing mushrooms, solidifying relationships with local partners.
On Behalf of The Board of Directors
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life Retail offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.
TheraPsil is a non-profit coalition of healthcare professionals, patients, and advocates dedicated to obtaining access to safe, effective, and legal psilocybin-assisted psychotherapy for Canadians experiencing end-of-life distress.
Investor Relations: firstname.lastname@example.org
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Project Solace, the Company’s participation in Project Solace, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the anticipate benefits of Project Solace will not be realized as contemplated, or at all, the risk that the anticipated benefits of the Company’s participation in Project Solace will be realized as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.